AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.37B |
| Gross Profit (TTM) | $50.13B |
| EBITDA | $19.90B |
| Operating Margin | 23.50% |
| Return on Equity | 22.00% |
| Return on Assets | 8.02% |
| Revenue/Share (TTM) | $39.59 |
| Book Value | $32.43 |
| Price-to-Book | 4.99 |
| Price-to-Sales (TTM) | 3.97 |
| EV/Revenue | 4.532 |
| EV/EBITDA | 13.66 |
| Quarterly Earnings Growth (YoY) | 2.50% |
| Quarterly Revenue Growth (YoY) | 6.40% |
| Shares Outstanding | $1.55B |
| Float | $1.41B |
| % Insiders | 0.05% |
| % Institutions | 64.96% |
Volatility is currently expanding
Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion.
Investors need to pay close attention to AZN stock based on the movements in the options market lately.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry thinking about a kind of dealmaking it has avoided for more than a decade.
The logic of a pharma megamerger is questionable, but AstraZeneca's record isn't.
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers.
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a Financial Times report over the weekend that the FTSE 100 drugmaker is in discussions over a merger with US rival Bristol Myers Squibb.
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Holz framed the logic bluntly. “If you take these two companies and you slash expenses, that would be the main thing here.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
